drugset / Trial / NCT01621386

Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

NCT01621386

Phase 1 Completed 34 enrolled Hal C Charles Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This study will explore the utility of magnetic resonance imaging (MRI) to assess ventilatory defects that occur due to asthma, determine the sensitivity and specificity of MRI in response to drug treatment, and whether MRI can serve as a biomarker of treatment effects due to asthma therapy.

Timeline

Start
2013-01
Primary completion
2015-09
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg Oral
Subject Prednisone Other / unclassified 20 mg Oral

Indications